Multiple sclerosis

Thompson, Alan J.; Baranzini, Sergio E.; Geurts, Jeroen J. G.; Hemmer, Bernhard; Ciccarelli, Olga

doi:10.1016/s0140-6736(18)30481-1

Cited by 1,279 publications

(1,061 citation statements)

References 144 publications

Supporting

Mentioning

1,021

Contrasting

Unclassified

Order By: Relevance

“…Multiple sclerosis (MS) is a chronic autoimmune disease of the CNS, leading to progressive deterioration of motor, sensory, vegetative and cognitive functions [180,181]. The pathogenesis of MS encompasses both features of acute and subacute inflammation, and of chronic neurodegeneration, mainly as a result of the former.…”

Section: Matrix Metalloproteinases In Multiple Sclerosismentioning

confidence: 99%

“…Because of these similarities with neuroinfectious disease with subsequent neuroinflammation and brain damage, MS is also covered in the present review. There are more than 2.3 million patients worldwide, making MS the most important neurological diseases of young adulthood [180]. The disease affects predominantly Caucasians with highest prevalence in populations of Northern European origin.…”

Section: Matrix Metalloproteinases In Multiple Sclerosismentioning

confidence: 99%

“…The disease affects predominantly Caucasians with highest prevalence in populations of Northern European origin. The cause of MS remains unknown, while there is strong evidence for an interplay of genetic and environmental factors (smoking, lack of sun exposure/vitamin D deficiency, Epstein-Barr virus (EBV) infection) responsible for susceptibility and course of disease [180,181]. The classical understanding of MS pathogenesis is based on three essential paradigms.…”

Section: Matrix Metalloproteinases In Multiple Sclerosismentioning

confidence: 99%

See 2 more Smart Citations

MMPs and ADAMs in neurological infectious diseases and multiple sclerosis

Muri

Leppert

Grandgirard

et al. 2019

Cell. Mol. Life Sci.

View full text Add to dashboard Cite

Metalloproteinases-such as matrix metalloproteinases (MMPs) and a disintegrin and metalloproteinases (ADAMs)-are involved in various diseases of the nervous system but also contribute to nervous system development, synaptic plasticity and neuroregeneration upon injury. MMPs and ADAMs proteolytically cleave many substrates including extracellular matrix components but also signaling molecules and receptors. During neuroinfectious disease with associated neuroinflammation, MMPs and ADAMs regulate blood-brain barrier breakdown, bacterial invasion, neutrophil infiltration and cytokine signaling. Specific and broad-spectrum inhibitors for MMPs and ADAMs have experimentally been shown to decrease neuroinflammation and brain damage in diseases with excessive neuroinflammation as a common denominator, such as pneumococcal meningitis and multiple sclerosis, thereby improving the disease outcome. Timing of metalloproteinase inhibition appears to be critical to effectively target the cascade of pathophysiological processes leading to brain damage without inhibiting the neuroregenerative effects of metalloproteinases. As the critical role of metalloproteinases in neuronal repair mechanisms and regeneration was only lately recognized, the original idea of chronic MMP inhibition needs to be conceptually revised. Recently accumulated research urges for a second chance of metalloproteinase inhibitors, which-when correctly applied and dosed-harbor the potential to improve the outcome of different neuroinflammatory diseases.Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

show abstract

Section: Matrix Metalloproteinases In Multiple Sclerosismentioning

confidence: 99%

Section: Matrix Metalloproteinases In Multiple Sclerosismentioning

confidence: 99%

Section: Matrix Metalloproteinases In Multiple Sclerosismentioning

confidence: 99%

See 1 more Smart Citation

MMPs and ADAMs in neurological infectious diseases and multiple sclerosis

Muri

Leppert

Grandgirard

et al. 2019

Cell. Mol. Life Sci.

View full text Add to dashboard Cite

show abstract

“…Another important area of development is that of induction versus escalation therapy . The current approach to treatment of paediatric‐onset multiple sclerosis involves initiation of treatment with safer but probably less‐efficacious first‐line therapies, then subsequently proceeding to more‐efficacious second‐line therapies as required (‘escalation’).…”

Section: Future Perspectives and Areas Of Researchmentioning

confidence: 99%

Paediatric multiple sclerosis: a new era in diagnosis and treatment

Duignan

Brownlee

Wassmer

et al. 2019

Develop Med Child Neuro

Self Cite

View full text Add to dashboard Cite

Multiple sclerosis is a chronic immune‐mediated demyelinating disease of the central nervous system. The diagnosis of multiple sclerosis in children, as in adults, requires evidence of dissemination of inflammatory activity in more than one location in the central nervous system (dissemination in space) and recurrent disease over time (dissemination in time). The identification of myelin oligodendrocyte glycoprotein antibodies (MOG‐Ab) and aquaporin‐A antibodies (AQP4‐Ab), and the subsequent discovery of their pathogenic mechanisms, have led to a shift in the classification of relapsing demyelinating syndromes. This is reflected in the 2017 revised criteria for the diagnosis of multiple sclerosis, which emphasizes the exclusion of multiple sclerosis mimics and aims to enable earlier diagnosis and thus treatment initiation. The long‐term efficacy of individual therapies initiated in children with multiple sclerosis is hard to evaluate, owing to the small numbers of patients who have the disease, the relatively high number of patients who switch therapy, and the need for long follow‐up studies. Nevertheless, an improvement in prognosis with a globally reduced annual relapse rate in children with multiple sclerosis is now observed compared with the pretreatment era, indicating a possible long‐term effect of therapies. Given the higher relapse rate in children compared with adults, and the impact multiple sclerosis has on cognition in the developing brain, there is a question whether rapid escalation or potent agents should be used in children, while the short‐ and long‐term safety profiles of these drugs are being established. With the results of the first randomized controlled trial of fingolimod versus interferon‐β1a in paediatric multiple sclerosis published in 2018 and several clinical trials underway, there is hope for further progress in the field of paediatric multiple sclerosis. What this paper adds Early and accurate diagnosis of multiple sclerosis is crucial. The discovery of antibody‐mediated demyelination has changed the diagnosis and management of relapsing demyelination syndromes. Traditional escalation therapy is being challenged by induction therapy.

show abstract

“…Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system 1 . The estimated prevalence ranges between 18.6 and 265 cases/100 000 inhabitants 2 .…”

Section: Introductionmentioning

confidence: 99%

Consensus document on the multidisciplinary management of neurogenic lower urinary tract dysfunction in patients with multiple sclerosis

Polo

Adot

Allué

et al. 2020

Neurourology and Urodynamics

View full text Add to dashboard Cite

Aim: Neurogenic lower urinary tract dysfunction (NLUTD) is very common in multiple sclerosis (MS) patients. Early diagnosis and treatment are crucial to avoid irreversible damage and improve quality of life. Our aim was to develop recommendations to improve NLUTD identification in MS patients, along with their referral and management.Methods: A multidisciplinary group of 14 experts in the management of patients with MS and NLUTD (nine urologists, three neurologists, and two rehabilitators) was selected. A comprehensive review of the literature was undertaken and a set of recommendations was generated and submitted to a Delphi panel of 114 experts. Recommendations were presented according to the grade of agreement (GA). Results: Early diagnosis in asymptomatic patients with risk factors for complications is recommended (GA 94%). Postvoid residual volume should be measured if changes in urinary symptoms (GA 87%), preferably ultrasoundguided (GA 86%). Early referral to urologist is recommended if urinary incontinence (GA 91%), significant post-void residual volume (94%), quality of life impairment (GA 98%) and recurrent urinary infections (GA 97%). The initial

show abstract

Multiple sclerosis

Cited by 1,279 publications

References 144 publications

MMPs and ADAMs in neurological infectious diseases and multiple sclerosis

MMPs and ADAMs in neurological infectious diseases and multiple sclerosis

Paediatric multiple sclerosis: a new era in diagnosis and treatment

Consensus document on the multidisciplinary management of neurogenic lower urinary tract dysfunction in patients with multiple sclerosis

Contact Info

Product

Resources

About